Candida albicans
- Generic Name
- Candida albicans
- Brand Names
- Candin
- Drug Type
- Biotech
- Unique Ingredient Identifier
- 4D7G21HDBC
- Background
Candida albicans is a fungus which can provoke allergic reactions. Candida albicans is used in allergenic testing.
Fecal Microbiota Therapy Shows 95% Success Rate in Preventing Recurrent C. difficile Infection
• Phase 3b trial demonstrates colonoscopic administration of Rebyota (fecal microbiota live-jslm) achieves 95.1% treatment success in preventing recurrent C. difficile infection with minimal adverse events.
• The CDI-SCOPE study spanning 12 US sites received overwhelmingly positive physician feedback, with over 90% reporting satisfaction with both the procedure and patient outcomes.
• This microbiota-based therapy represents a significant advancement over traditional fecal transplant approaches by providing a more structured and accessible restoration technique for gut microbiome.
Breakthrough Nanotechnology: Targeted Liposomes Dramatically Enhance Antifungal Treatment Against Resistant Candida
• Brown University researchers have developed peptide-decorated liposomes that specifically target Candida cells, dramatically increasing antifungal drug effectiveness while sparing healthy human cells.
• The innovative approach uses penetratin peptides as molecular "homing devices" on liposomes containing posaconazole, inhibiting fungal growth at concentrations up to eight times lower and preventing biofilm formation at doses 1,300 times lower than conventional treatments.
• In mouse models of Candida albicans infection, the targeted liposome delivery system reduced fungal burden by 60% compared to standard drug-loaded liposomes, offering new hope against increasingly drug-resistant fungal pathogens.
Nielsen BioSciences Completes Phase 3 Enrollment for Novel Wart Treatment CANDIN
• Nielsen BioSciences has completed enrollment of 325 subjects across the US and Japan in a Phase 3 trial evaluating CANDIN for common wart treatment, with results expected by end of 2025.
• The trial investigates CANDIN, a Candida albicans-based immunological therapy, as a potential alternative to traditional wart removal methods that can damage skin.
• The study aims to assess complete wart resolution in patients aged 12 and older through bi-weekly injections, with Nielsen planning US regulatory submissions and partnership with Maruho for Japanese commercialization.
T2 Biosystems' T2Candida Panel Receives FDA Clearance for Pediatric Use
• T2 Biosystems has secured FDA clearance to market its T2Candida Panel for pediatric patients, expanding its reach to over 200 children's hospitals in the U.S.
• The T2Candida Panel is the only FDA-cleared diagnostic test capable of detecting sepsis-causing Candida species directly from blood within 3-5 hours.
• Clinical studies demonstrate the T2Candida Panel's superior speed and sensitivity compared to traditional blood culture methods, enabling faster, targeted antifungal treatment.
• The FDA clearance allows for improved patient outcomes and reduced healthcare costs through quicker diagnosis and treatment of invasive candidiasis in children.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath